As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.
Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)
Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)
Harnessing the power of microglia to
transform treatments for neuro-
degenerative diseases (NASDAQ: VIGL)
Broadening the reach and
impact of precision medicine
to more people with cancer
Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)
Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)
Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016
Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019
Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)
Harnessing the immune system to
defeat cancer with tumor-selective
immunotherapies (NASDAQ: XLO)
Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)
Delivering medicines for rare,
autoimmune, and inflammatory diseases
IPO July 2011 (NASDAQ: HZNP)
Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020
Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)
Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020
Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016
Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders
Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)
Treating cancer’s toughest
tumors by harnessing the power
of precisely delivered radiation
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics
Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)
Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)
Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)
Advancing targeted protein
degradation to target previously
“undruggable” disease pathways